Inventiva
Research Inventiva (IVA) on Bullrun: market cap USD 973.87M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIVA
- ExchangeNASDAQ
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 973.87M
- Financial periodQ4 2025
Valuation Snapshot
latest market cap is USD 973.87M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 973.87M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 898.27M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 204.72M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 233.44M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 187.92M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 558.33M | n/a | n/a | n/a |
About Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Inventiva's market cap?
Inventiva's market capitalization is USD 973.87M.
What does Inventiva do?
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis.